Please login to the form below

Not currently logged in
Email:
Password:

Duaklir

This page shows the latest Duaklir news and features for those working in and with pharma, biotech and healthcare.

Circassia seeks shift to AIM after failing LSE criteria

Circassia seeks shift to AIM after failing LSE criteria

Duaklir (aclidinium/formoterol) which is under regulatory review in the US with a verdict due by the end of March. ... The agreement between Circassia and AZ also includes a deferred Tudorza option payment of $20m payable upon approval of Duaklir, plus a

Latest news

More from news
Approximately 3 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2017 Deal Watch March 2017

    AstraZeneca will complete the development of Duaklir (for which Circassia will contribute $462.5m) and will manufacture and supply the products. ... 250. AstraZeneca. Circassia Pharmaceuticals. Strategic collaboration. Tudorza (marketed) and Duaklir

  • Deal Watch table for November 2014 Deal Watch table for November 2014

    Eklira and Duaklir. Business unit acquisition. 3, 075. Pfizer / Merck KGaA.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
claire@dovetailstrategies.com

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics